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(BBB) and access the brain parenchyma to treat neurological diseases. However, once in the
brain the extent to which receptor-mediated reverse transcytosis clears mAb from the
brain is unknown. The aim of this study was to determine the contribution of the neonatal
Fc-receptor (FcRn) in rat brain efﬂux employing two different in vivo drug delivery models.
Two mAb variants with substantially different afﬁnities to FcRn, and no known neuronal
targets, (IgG1 N434A and H435A) were administered to rats via intranasal-to-central
nervous system (CNS) and intra-cranial dosing techniques. Levels of full-length IgG were
quantiﬁed in serum and brain hemispheres by a sensitive enzyme-linked immunosorbent
assay (ELISA). Following intra-nasal delivery, low cerebral hemisphere levels of variants
were obtained at 20 min, with a trend towards faster clearance of the high FcRn binder
(N434A); however, the relatively higher serum levels confounded analysis of brain FcRn
contribution to efﬂux. Using stereotaxic coordinates, we optimized the timing and dosing
regimen for injection of mAb into the cortex. Levels of N434A, but not H435A, decreased in
the cerebral hemispheres following bilateral injection into the rat cortex and higher levels
of N434A were detected in serum compared to H435A after 24 h. Immunohistochemical
staining of human IgG1 in sections of cortex was consistent with these results, illustrating
relatively less intense immunostaining in N434A than H435A dosed animals. Using two
in vivo methods with direct cranial administration, we conclude that FcRn plays an
important role in efﬂux of IgG from the rat brain.
& 2013 Elsevier B.V. All rights reserved.r B.V. All rights reserved.
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The blood brain barrier (BBB) is the protective layer separating
the systemic circulation from the brain extracellular ﬂuid.
It is made up of tight junctions between endothelial cells on
cranial capillaries, a thick basement membrane and astro-
cytic end-feet. The BBB serves to restrict bacteria and other
large hydrophilic molecules from entering the brain parench-
yma, while allowing small hydrophobic molecules and nutri-
ents to enter.
Pharmacologic treatment of neurologic diseases has relied
on brain penetration of small lipophilic molecules. However,
where high selectivity and potency is desirable, an alternative
therapeutic approach could be the use of monoclonal anti-
bodies (mAbs). Immunoglobulin-Gs (IgGs), along with other
plasma proteins, are large hydrophilic molecules that are
unable to pass through the BBB in sufﬁcient quantity to be
efﬁcacious when systemically administered (Poduslo et al.,
1994). Researchers are currently experimenting with receptor-
based brain endothelial transcytosis, such as using the trans-
ferrin receptor (Bickel et al., 1994; Pardridge et al., 1991; Yu
et al., 2011) or insulin receptor (Boado et al., 2007; Pardridge
et al., 1995) for IgGs to enter the brain parenchyma. However,
once mAbs enter the brain, the extent to which they are
cleared by receptor-mediated reverse transcytosis is not well-
known.
Evidence of the involvement of an Fc-receptor in the
clearance of IgG from the central nervous system (CNS) has
been shown by a shorter half-life of IgG, compared to IgM
(antibody that lacks Fc region), in both rat and monkey
cerebrospinal ﬂuid (Bergman et al., 1998). Moreover, efﬂux of
IgG though the BBB is competitively inhibited by the addition
of Fc fragments (Boado et al., 2007; Zhang and Pardridge, 2001).
Indeed, the Fc-receptor mediated Aβ-IgG efﬂux mechanism
has been shown to facilitate the clearance of IgG complexes
from brains (Deane et al., 2005).
There are data to both support and refute the role of the
neonatal Fc-receptor (FcRn) in IgG efﬂux from the brain. Using
non-compartment mathematical modeling in mice which lack
FcRn functionally, there was no apparent difference in efﬂux
compared to wild-type mice based on labeled IgG and residual
blood volume (Abuqayyas and Balthasar, 2013; Garg and
Balthasar, 2009). FcRn is visualized by confocal microscopy in
brain microvasculature endothelial cells (Schlachetzki et al.,
2002), but whether the receptor is involved in efﬂux in addition
to its role in recycling IgG is unknown. In vascular endothelial
cells, IgG is taken up from the circulation by non-speciﬁc ﬂuid-
phase pinocytosis where it binds to FcRn in the acidic endo-
some. It is recycled to the capillary lumen where it has a long
half-life (Roopenian and Akilesh, 2007). It is therefore postu-
lated that expression of FcRn located in brain endothelial cells
(Schlachetzki et al., 2002) may be involved in the efﬂux of IgGs
from the brain.
The aim of the current study was to deﬁne the role of FcRn
in IgG efﬂux from the rat brain using two variants of a
recombinant human IgG1 mAb that either had increased
FcRn binding (IgG1 N434A) or decreased FcRn binding (IgG1
H435A) compared to wild-type by incorporating mutations at
the 434 and 435 amino acid positions (EU numbering) (Firanet al., 2001; Yeung et al., 2009). The monoclonal antibodies
were generated to target respiratory syncytial virus (RSV) and
would not be expected to bind to targets in the brain. A
human mAb was used to avoid potentially faster clearance of
mouse mAb dosed to rats, and enable detection of the human
Fc in rat tissues. Studies were 24 h or less to avoid differences
in serum levels due to the relationship of FcRn binding
afﬁnity and circulating half-life. The two variants have been
shown to have rat FcRn binding afﬁnities, of 77 nM for N434A
and 41000 nM for H435A at pH 6.0 (Kliwinski et al., 2013).2. Results
2.1. Physicochemical characteristics of the FcRn binding
variants
Both variants had identical pI values of 7.2. The circular
dichroism (CD) spectra for both the near and far ultra-violet
ranges showed very similar secondary and tertiary protein
structure for both of the variants. They had the same Size
Exclusion Chromatography (SEC) proﬁles with no covalent
aggregates, and were stable at 25 1C for 4 d. There was no
interaction with mucins, which would confound their deliv-
ery by intranasal route (data not shown).
2.2. Pharmacokinetics of FcRn binding variants after
intranasal-to-CNS administration
FcRn binding variants (H435A and N434A) were administered
intranasally into each nostril of rats (40 nmol/rat) and plasma
was collected after 20, 40, and 90 min post-dose. The levels of
the FcRn binding variant increased to levels that reached
200 ng/mL in the circulation at a greater rate than the non-
FcRn binding variant (Fig. 1A). Rat brain hemispheres were
collected after brain perfusion, at 20, 40, and 90 min post-
dose from different rats. FcRn binding variants delivered into
the brain (ng/g) were detected by an ELISA-based MSD assay
that detects full-length mAb (Fig. 1B). N434A entered the
brain at a faster rate than H435A and peaked at a higher level
at 20 min. Despite the greater degree of uptake of N434A,
levels of this variant dropped to very low levels within the
same 90 min timeframe as H435A. Statistical comparison of
the AUC values generated for each variant showed a statis-
tically signiﬁcant difference (N434A AUC 1637 ng min/g vs.
H435A AUC 827 ng min/g, Po0.05), representing an approxi-
mately two-fold faster rate of efﬂux for N434A compared
to H435A.
To monitor that test article was correctly deposited with
the tube insertion technique; olfactory epithelia from both
nostrils were collected at 20, 40, and 90 min post-dose and
analyzed for FcRn binding variants. The PK proﬁles of each
are shown in Fig. 1C and D. In both epithelia, the N434A
variant was cleared at a much faster rate than the H435A, and
the AUC values for each were signiﬁcantly different (left AUC
H435A 2.2107 ngmin/g vs. left AUC N434A 1.4107 ngmin/g,
P¼0.01; right AUC H435A 2.6107 ngmin/g vs. right AUC
N434A 1.6107 ngmin/g, Po0.01). These data are indicative of
an active FcRn mediated efﬂux mechanism removing the FcRn-
binding N434A variant from the olfactory epithelium.
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Fig. 1 – PK proﬁles of variants after intranasal-to-CNS administration: H435A or N434A were administered intranasally to rats.
A total of 50 ll, of a 60 mg/ml solution of either variant, was applied to each nostril sequentially over 12 min (425 ll, right
and left, 4 min interval). (A) Serum was collected at 20, 40, and 90 min post-dose and full-length IgG quantiﬁed. Animals were
euthanized at 20, 40, and 90 min post-dose and (B) hemispheres (n¼12) and (C) left and (D) right olfactory epithelia (n¼6)
analyzed for N434A (■) or H435A (●). Values are mean 7 SEM.
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Fig. 2 – Time-course of serum levels of IgG1 N434A: serum
levels (ng/mL) were measured from rats (n¼15) at 5 and
3 min, and 1, 2, and 4 h following intra-cranial
administration of IgG1 N434A (2.4 lg; 2 mg/ml). Intact IgG1
was quantiﬁed using the MSD assay.
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 1 152.3. Pharmacokinetics of FcRn binding variants after
intra-cranial administration
2.3.1. Serum levels of the FcRn binding IgG variant, N435A,
increase with time
The contribution of FcRn in IgG brain efﬂux was suggestive of
FcRn-mediated efﬂux but not conclusive after intranasal
administration due to the relatively low brain levels and
differences in serum levels of the variants. Therefore, we
complimented these studies by direct intracranial stereotaxic
administration. Preliminary experiments were performed to
determine a dose that, when administered into the brain via
stereotaxic coordinates to the parietal cortex, would result in
detectable serum levels. To do this, rats were maintained under
anesthesia for 4 h after unilateral administration of the FcRn
binding variant (N434A; 2.0 mg/mL; 1.2 mL) into the right anterior
SiFl region of the somatosensory cortex. Serum levels of intact
IgG were measured at 5, 30, 60, 120, 180, and 240 min. Following
intra-cranial administration of the antibody, low but detectable
levels of full-length IgG in serum were detected by 30min.
Serum levels continued to increase up to the termination of the
experiment at 4 h. The rate of efﬂux was fairly stable from 0 to
180min with an average efﬂux rate of 0.4 ng/mL/h. The rate
increased to 0.9 ng/mL/h between 180 and 240 min, with serum
levels of 2.170.5 ng/mL at the ﬁnal time point (Fig. 2).2.3.2. Unilateral intra-cranial dosing of IgG variants
Having established that intact IgG serum levels following
intra-cranial administration increased over time, but had not
reached maximal levels after 4 h, serum levels of FcRn binding
variants (N434A, with the FcRn low binding control IgG, H435A)
were measured up to 24 h. A 2.4 mg dose (2.0 mg/mL) of either
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Fig. 3 – Unilateral intra-cranial dosing: anesthetized Sprague
Dawley rats (n¼6/group) were intra-cranially (anterior right
hemisphere) administered (2.4 lg; 2 mg/ml) of either IgG1
N434A or IgG1 H435A. Intact IgG1 was quantiﬁed using the
MSD assay. (A) Serum levels (ng/mL) were measured at
5 min, and 4 and 24 h following intra-cranial administration
of IgG1 N434A (■) or IgG1 H435A (●). (B) After the ﬁnal blood
draw, brains were removed, homogenized and intact IgG
quantiﬁed IgG1 N434A (solid) or IgG1 H435A (stripes).
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 116N434A or H435A was administered into the right anterior SiFl
region of the cortex of anesthetized rats. The animals in this
study were anesthetized until after the 4 h blood draw then
allowed to recover. Consistent with the preliminary study,
levels of full-length IgG in the serum at 5 min were below the
LLOQ for all rats dosed, thus conﬁrming that no surgical
damage was performed that would lead to systemic contam-
ination. Levels of N434A and H435A were similar 4 h after
administration (4.471.9 and 3.471.9 ng/mL, respectively), but
after 24 h there tended to be higher levels of the N434A FcRn-
binding variant (20.675.8 and 11.973.1 ng/mL, respectively)
which did not attain a level of statistical signiﬁcance (Fig. 3A).
In brain tissue at the earliest time point of 5 min, levels of
N434A (FcRn binding variant) were 17167354 ng/g of tissue
and similar to that expected based on dose administered
(average mass of a hemisphere was 1.0 g). Levels decreased
by approximately 40% after 24 h whereas levels of the non-
binding variant H435A in the brain hemispheres were
unchanged over time up to 24 h (Fig. 3B). Levels in the
cerebellum, brainstem, and lymph nodes were low and no
difference was detected between the variants (data not
shown).2.3.3. Bilateral intra-cranial dosing of IgG variants
A high concentration of mAb administered unilaterally may
saturate the FcRn receptor in the vicinity of the injection, thus
limiting the contribution of receptor-mediated efﬂux. This could
explain the lack of a clear difference between the two variants
following unilateral administration; therefore, the variants were
dosed bilaterally. The total brain dose of 2.4 mg was the same as
in the previous study, but a 1.2 mg (0.6 mL) dose of either N434A
or H435A was administered bilaterally. Serum levels were
measured at 5 min, 4, and 24 h and rats were allowed to recover
from anesthesia immediately after surgery. After 24 h, N434A
serum levels reached 25.975.2 ng/mL which was signiﬁcantly
greater (Po0.001) than the serum levels of the low FcRn binding
variant, H435A, at 6.670.6 ng/mL. The rate of efﬂux of N434A
was calculated to be three times greater than H435A (Fig. 4A).
In a separate group of animals, brain hemispheres were
excised 5 min after either N434A or H435A antibody admin-
istration. Levels of N434A detected at 5 min were 2.270.5 mg/g
of tissue (average mass of the hemispheres was 1.0 g) which
was the expected range after administration. After 24 h,
levels of N434A in the hemispheres decreased by 48%. Levels
of the non-FcRn binding mAb, H435A, did not change over the
same time period (Fig. 4B).
In order to visualize the presence of human IgG immuno-
histochemically in the rat brain, three animals were dosed
either N434A or H435A bilaterally into the SiFl region of the
cortex similar to the previous experiment. After 24 h rats were
perfused and brains prepared for immunohistochemistry
using an anti-human Fc rabbit polyclonal in thin (5 mm) brain
sections. Brains were processed for routine histology (hema-
toxylin and eosin and Luxol fast blue), as well as human IgG
and anti-rabbit IgG negative controls. At 24 h after dosing both
N434A and H435AmAb variants were visualized in brain tissue
(Fig. 5). There was a range of staining intensity visualized in
sections at an equivalent coronal plane in the region of the
somatosensory cortex in pyramidal and supporting cells that
was localized to the cortex or spread into the corpus callosum
region. The staining intensity of N434A (Fig. 5A) in the cortex
was consistently less than brains injected with H435A (Fig. 5B).
There was no speciﬁc staining detected in PBS microinjected
brains (Fig. 5C) or mAb injected brains incubated in serum
(Fig. 5D). Semi-quantitative immunostaining scores supported
the impression that less of the FcRn binding variant was
visualized in brain after 24 h (HA¼7.071.4 vs. NA¼4.471.7
of a total of 12.0 maximum staining; P¼0.3 by unpaired t-test),
which is consistent with greater efﬂux of the FcRn binding
mAb variant.3. Discussion
This study used two in vivo drug delivery models in rats,
intranasal-to-CNS and direct intra-cranial dosing, to determine
the contribution of FcRn to IgG receptor-dependent reverse-
transcytosis (efﬂux) from the brain parenchyma to the circula-
tion. Following administration into the brain by these two
methods, greater amounts of the FcRn binding variant N434A
were detected in the circulation compared to the low-binding
FcRn variant control, H435A. Following intra-cranial adminis-
tration, levels of H435A in the brain hemispheres did not
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Fig. 4 – Bilateral intra-cranial dosing: anesthetized Sprague
Dawley rats (n¼10/group) were intra-cranially (anterior
hemisphere: right and left) administered (1.2 lg each site;
2 mg/ml) either IgG1 N434A or IgG1 H435A. Intact IgG1 was
quantiﬁed using the MSD assay. (A) Serum levels (ng/mL)
were measured at 5 min, and 4 and 24 h following intra-
cranial administration of IgG1 N434A (■) or IgG1 H435A (●).
(B) After the ﬁnal blood draw, hemispheres were removed,
homogenized, and intact IgG quantiﬁed (ng/g brain tissue) in
total hemispheres. Key: 5 min (solid), 24 h (squares).
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 1 17change over a 24 h period while the levels of N434A signiﬁcantly
decreased over time.
Intranasal-to-CNS delivery was used initially because it is a
non-invasive technique. For maximal delivery to the brain
hemispheres, the test article had to be applied directly to the
olfactory epithelium of the nose (Thorne et al., 2004). Test
article then moves in a paracellular fashion, driven by diffu-
sion, past the olfactory epithelium, and into the nasal lamina
propria beneath (Dhuria et al., 2010). This space is contiguous
with channels through the cribriform plate, which contain the
axons of the olfactory neurons. Earlier studies have shown
that a certain percentage of cerebrospinal ﬂuid (CSF) exits the
brain through the cribriform plate and enters nasal lymphatics
which drain into the cervical lymph nodes (Bradbury et al.,
1981; Bradbury and Westrop, 1983; Cserr et al., 1992). This
process could represent a hindrance to molecular ﬂow into the
brain. However, subsequent ultra-structural studies have
demonstrated the existence of neuronal channels that tra-
verse the subarachnoid space (Field et al., 2003; Li et al., 2005)
thus preventing direct interaction with CSF. These channels
are believed to provide direct access into the parenchyma of
the brain hemispheres (Dhuria et al., 2010; Lochhead andThorne, 2012). Functional studies using both small and large
molecules have shown delivery to the hemispheres via this
mechanism despite this potential hindrance. The main driving
force for uptake is the concentration gradient of the test article
(Barakat et al., 2006; Evseev et al., 2010; Furrer et al., 2009;
Gorbatov et al., 2010; Hoekman and Ho, 2011; Romanova et al.,
2010; Sipos et al., 2010). However, there are two main factors
that do impinge on the efﬁciency of CNS uptake of a molecule
using this technique: those related to formulation, and those
related to physicochemical characteristics. The formulation
considerations include the type, pH, and tonicity of the buffer,
and/or the presence of excipients representing transport enha-
ncers, stabilizers, and muco-adhesives (Pujara et al., 1995;
Washington et al., 2000). The important physicochemical
characteristics include molecular size, hydrophobicity/hydro-
philicity, surface charge, and mucus compatibility (Vyas et al.,
2006). The test articles used in these studies are similar in
terms of their physicochemical characteristics. Both H435A
and N434A have pI values of 7.2, differ by just one amino acid,
and have virtually identical secondary and tertiary structures
as measured by circular dichroism. Functionally, they only
differ in their afﬁnity for the FcRn receptor, have no known
targets in the brain and therefore are uniquely suited to use
address the role of FcRn in IgG efﬂux from the brain.
Following intra-nasal administration, the data suggested
that FcRn contributed to reverse-transcytosis of IgGs from the
rat brain, but were inconclusive, in part because of different
levels of mAb remaining in the olfactory epithelium.With lower
than expected brain levels after dosing intranasally at 40 nmol/
rat, and unexpected 100-fold higher serum levels (compared to
intra-cranial administration), it is unclear whether variants
entered the brain hemispheres prior to their entering the
vascular compartment and confounded the interpretation of
brain FcRn contribution to levels in the serum. However, AUC
calculated data of the variant levels that did enter the hemi-
spheres did provide a statistical signiﬁcant difference in the rate
of efﬂux of the two variants that did enter the brain. These data
suggest a role of FcRn in the reverse-transcytosis of IgGs from
the rat brain.
Following unilateral stereotaxic administration, there was
a tendency for greater amounts of N434A in the serum after
24 h compared to H435A. Importantly, potential damage to
the tissue vasculature during the surgery could have resulted
in systemic contamination; however, the serum levels at
5 min after administration were below the lower level of
quantiﬁcation in all animals suggesting the absence of such
damage. Sample size (n¼6) may have been the reason for the
lack of statistical signiﬁcance, as well as potential saturation
of FcRn due to high local concentrations of the compound
over the duration of the study (r24 h). To avoid this problem,
the study was repeated with the mAbs dosed bilaterally at the
same co-ordinates for both right and left brain hemispheres.
The total brain dose was identical to the unilateral dosing,
but the local concentration at either brain hemisphere was
halved. A signiﬁcant increase in serum levels at 24 h and a
decrease in total brain hemisphere levels were noted for the
higher afﬁnity FcRn binding variant compared to the low
FcRn binding variant. Together these data conﬁrm the trends
shown in the intranasal and unilateral intra-cranial admin-
istration studies; and are in agreement with the previous
PBS; anti-human IgG 
N434A; anti-human IgG 
H435A; rabbit serum 
H435A; anti-human IgG 
Fig. 5 – Greater levels of IgG1 H435A than IgG1 N434A in brain: representative examples of IgG-immunoreactivity in rat brains
24 h after intra-cranial administration of (A) IgG1 N434A; anti-hIgG1; (B) IgG1 H435A; anti-hIgG1; (C) PBS, anti-hIgG1, and (D)
IgG1 H435A, rabbit serum.
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 118studies that propose FcRn mediated efﬂux (Deane et al., 2005;
Deane et al., 2009; Zhang and Pardridge, 2001).
The opposite conclusion with regard to the role of FcRn in
IgG brain efﬂux was reached by two studies using two
different experimental methods. β-2-microglobulin knock-
out mice, which lack functional FcRn, and wild-type controls
showed no difference in brain-to-plasma AUC ratios after
intravenous administration of an I125 labeled mAb, leading
the investigators to conclude that FcRn does not signiﬁcantly
contribute the low exposure of mAb in brain (Abuqayyas and
Balthasar, 2013; Garg and Balthasar, 2009). In contrast another
study reported that brain clearance after systemically admi-
nistered mAb was reduced in FcRn/mice (Deane et al.,
2005; Deane et al., 2009).
The most signiﬁcant difference between the protocol used
in the studies with opposing conclusions (Abuqayyas and
Balthasar, 2013; Garg and Balthasar, 2009), and the protocol
used in the current study, and others (Zhang and Pardridge,
2001), was that IgG was administered directly into the brains of
rats and serum and brain levels were measured. The other
studies (Abuqayyas and Balthasar, 2013; Garg and Balthasar,
2009) involved administration of IgG into the circulation of
wild-type and FcRn knock-out mice and relied on the ability of
IgG to cross into the brain to measure AUC differences
between brain content and serum levels. There was no directevidence that the IgG crossed the BBB into the brain parench-
yma as the group did not measure IgG levels in the brain
directly, but instead measured levels in residual blood. It is
also unclear what the afﬁnity of their IgG antibody was to
murine FcRn. Therefore, there is limited evidence that FcRn
had the ability to play a role in the efﬂux within that
previously published study. Another disadvantage of this
protocol was their use of FcRn knock-out mice. With no FcRn,
the recycling and salvation of IgGs would not be present in
these mice so IgG half-life would be substantially decreased.
Although the study involving these mice was shortened to 4 d
to compensate for this, there would be signiﬁcantly less IgG in
the circulation after 4 d (95% less). This adds differences in
AUC of mAb in WT and knock-out mice confounding brain
exposure. Indeed, clearance was eight-fold faster in FcRn
knock-out mice compared to the other strains, as would be
expected (Abuqayyas and Balthasar, 2013). In addition, the
observed brain to plasma AUC ratio was greater in mice in the
second study and the data was adjusted for differences in
hematocrit (Abuqayyas and Balthasar, 2013; Garg and
Balthasar, 2009). The emphasis on mathematical modeling
may account for the differences in their conclusions compared
to the observations in FcRn knock-out mice where brain
clearance of a systemically administered mAb was lower than
wild type controls (Deane et al., 2005; Deane et al., 2009).
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 1 19In summary, this study demonstrates that FcRn plays an
important role in the efﬂux of IgGs. These results need to be
taken into account in future studies evaluating therapeutic
IgGs containing an Fc portion when targets in the brain are
investigated. As the variants in the present study did not
have a neuronal target, future studies should consider the
impact of target receptor occupancy for the therapeutic target
to determine the maintenance of IgG brain levels or when
investigating the relevance of FcRn-dependent efﬂux.4. Experimental procedure
4.1. Animals
Male Sprague Dawley rats, 7–10 weeks old (200–300 g) (Charles
River, Wilmington, MA, USA) were kept in plastic ﬁlter-topped
cages and allowed free access to food and water. All animal
studies were performed in accordance with the Federal Animal
Welfare Act and methods approved by the Institutional Animal
Care and Use Committee at Janssen R&D.
4.2. Monoclonal antibody preparation
The mAbs used in this study were variants of a recombinant
chimeric human IgG1 monoclonal antibody speciﬁc for human
respiratory syncytial virus (RSV). For intranasal dosing the FcRn
binding mutants, IgG1 H435A and IgG1 N434A, underwent
buffer exchange from phosphate-buffered saline (PBS). The
buffer used for exchange was 10mM histidine/5.5% sucrose
(pH 5.3), 150 mM NaCl. After three rounds of exchange,
the mutants were concentrated to 66.67mg/mL and pro-
pylene glycol was added to a ﬁnal concentration of 10%, making
the ﬁnal concentration of the mutants 60mg/mL. These pre-
parations were used for intranasal dosing.
4.3. Physicochemical characteristics of the FcRn binding
variants
The physiochemical characteristics of the two variants were
assessed and compared as this is a factor which can con-
tribute to a difference in intra-nasal uptake. The predicted
isoelectric point (pI) values of the variants were derived using
Vector NTI sequence analysis software (Invitrogen). Circular
dichroism (CD) spectroscopy to analyze structure was per-
formed on the variants (0.25 mg/mL in PBS) and compared to
PBS alone. Spectral acquisition was measured at 6 spectra
from 190–260 nm at 1 nm path length and 1 nm intervals with
a 2 s signal at 20 1C (Circular Dichroism Spectropolarimeter,
Model 400, Aviv). The CD spectra were averaged and the net
spectrum of the variants obtained by subtracting the average
PBS scores. Spectra were ﬁtted for species content using an
MWR of 106 g/mol (150 kDa).
4.4. Intranasal-to-CNS administration
Pre-dose plasma samples were collected from the animals via
tail vein a day prior to dosing. On the day of dosing rats were
anesthetized with sevoﬂurane (5.0–6.0% sevoﬂurane, 3.0 L/min
O2; Abbott Labs., Princeton, NJ, USA) while placed in a supineposition on an acrylic support with their heads positioned at a
451 angle to the horizon. A microcannula (BioTime, Berkeley,
CA, USA) was inserted to a depth of 1.5 cm into the right nostril
and either H435A or N434A (1.5 mg in 25 mL at a rate of 50 mL/
min) was infused by syringe pump (Harvard Apparatus, Cam-
bridge, MA, USA). After 4 min, the same variant was applied
into the left nostril and the alternating procedure repeated for a
total application of 50 mL/nostril, therefore 400 mmol/L. After the
ﬁnal dose, the microcannula was removed and inhalant anes-
thetic was continued for 8min with the animal supine and the
head angle maintained at a 451 angle. At 20min after the start
of the ﬁrst dose, animals were euthanized and tissues collected.
For longer time points, anesthesia was maintained for 20 min
and then removed and animals were allowed to awaken.
4.5. Intra-cranial administration
The animals were placed in a chamber for induction of
anesthesia with isoﬂurane (initially 2–4%) and then removed
and placed in a stereotaxic device (Knopf) on a surgical pad
maintained at 37 1C with a nose cone for maintenance of
anesthesia (2% isoﬂurane) (Cetin et al., 2006). Buprenorphine
(0.01–0.05 mg/kg) analgesia was administered sub-cutaneous.
A midline incision was made to expose the bregma and was
used to locate the ipsilateral primary somatosensory forelimb
(SiFl) (þ0.2 mm anterior and 4.0 mm lateral3.0 mm deep). For
unilateral administration, only the right hemisphere was dosed.
A drill with a small burr attachment was used to introduce a
1mm hole into the skull to allow entry for a Hamilton syringe
(5 mL) to inject the test article, either IgG1 N434A or IgG1 H435A
into the brain (antibodies were dosed in pH-neutral buffers (pH
7.4), unless otherwise stated). For unilateral administration a
1.2 mL bolus of test article (2.0 mg/mL) was administered at a rate
of 0.4 mL/min (total dose¼2.4 mg, or 14 mmol/L). For bilateral
administration the volume administered to each side was
halved (0.6 mL); therefore, the total dose administered was equal
to the unilateral administration. Care was taken to perform the
surgical procedure following aseptic techniques and a surgical
plane of anesthesia was maintained throughout the entire
procedure. The incisions of animals were closed and the
animals were allowed to recover from anesthesia following
the 5min baseline blood draw.
4.6. Blood and brain tissue collection and homogenization
Animals were given isoﬂurane to facilitate retro-orbital blood
draws of approx 100 mL. All blood samples were allowed to
stand for at least 30min, but no longer than 1 h, centrifuged at
3500 rpm for 15min and the serum separated and stored at
80 1C. Following the ﬁnal blood collection a full body perfu-
sion was performed to remove residual blood from the brain
via cardiac puncture using 60mL (15 mL/min, syringe pump)
of a PBS solution containing protease inhibitors (1 tablet/
10mL, Complete Mini, Roche, Indianapolis, IN, USA) and
5 mM EDTA. Following perfusion, the anterior cervical lymph
nodes were removed and placed in FastPrep tubes. The head
was then decapitated and the brain removed and halved into
two hemispheres (excluding the olfactory bulbs), brainstem
(hypothalamus to level of cistern magna of hindbrain), and
cerebellum. The olfactory epitheliums were collected following
b r a i n r e s e a r c h 1 5 3 4 ( 2 0 1 3 ) 1 3 – 2 120intranasal-to-CNS administration only. Brain tissues were
placed into pre-weighed lysis Matrix D tubes (MP Biomedical,
Cat# 6913-500) or IKA tubes (IKA Cat# 3703100) then re-
weighed and quickly frozen on dry ice and stored at 80 1C
until homogenization.
Brain hemispheres were homogenized in 1:10 homogeniza-
tion buffer (assume 1 g of tissue is 1 mL volume) (TBS 25mM
Tris [pH 7.8], 150 mM NaCl, 1% Triton X-100, 5 mM EDTA
and cOmplete, EDTA-free Protease Inhibitor Cocktail Tablets
[1 tablet/10mL]). The brain hemispheres were thawed and
homogenized in buffer solution using an IKA instrument (Ultra
Turrax, IKA Cat# 3645001) (setting# 6, 20 s). The left and right
olfactory epithelia were diluted in the same homogenization
buffer, and homogenized using the Bio101 FastPrep instru-
ment (6.5 m/s; 40 s). Full length IgG in the brain and tissue
samples was quantiﬁed within 24 h of homogenization.4.7. Full-length human IgG detection
Full-length IgG antibodies were quantiﬁed using the Meso
Scale Discovery (MSD) electrochemiluminescent assay. The
mAbs used in this study were a recombinant chimeric human
IgG1 monoclonal antibody speciﬁc for human respiratory
syncytial virus (RSV). An anti-idiotypic antibody speciﬁc for
the anti-RSV IgGs was labeled with sulfo-NHS-LC-biotin and
used as a capture antibody. A pan anti-human IgG1/IgG2
antibody labeled with MSD Sulfo-TAG NHS Ester was used as
the detection antibody. The electrochemiluminescent labels
added emit light when electrochemically stimulated. Electro-
des bound to the sample-sandwich initiate the detection
process. A standard curve for the anti-RSV IgGs in neat rat
serum was observed over the range of 50,000–50 pg/mL. The
lower limit of quantiﬁcation (LLOQ) was 0.5 ng/mL using 25 mL
of neat rat serum.4.8. Immunohistochemistry
At 24 h after intracranial dosing (3 dosed N434A, 3 dosed H435A,
and one control dosed PBS) and whole body blood perfusion
(10% neutrally buffered formalin, NBF), the brain hemispheres
were removed and a 1mm section proximal to the site of
dosing was placed between two biopsy sponges and ﬁxed in
10% NBF. The rats used in this study were separate from the
previous efﬂux study. Following dehydration, the tissues were
exposed to the primary antibody, human IgG1 (1 mg/mL; 1 h;
Epitomics), then stained and counter-stained and dehydrated
further. The above procedures were completely automated
using the TechMate 500 (BioTek Solutions). Positive staining
was indicated by the presence of a brown chromogen (DAB-
HRP) reaction product. Representative images were obtained
with an Olympus Microﬁre digital camera (M/N S97809)
attached to an Olympus BX60 microscope. Samples were
individually scored on a semi-quantitative basis for human
IgG immunostaining. Each sample received an intensity human
IgG score per region of staining from each hemisphere. These
regions were Pyramidal Cells, Other Neural & Support Cells, and
Corpus Callosum Area. Intensity scores were graded on a 5
point scale; 0, 1þ, 2þ, 3þ, or 4þ staining intensity (where 0¼no
staining and 4þ¼completely saturated staining). The scoreswere then added together to obtain a sample total score
(maximum¼12).
4.9. Statistical analyses
4.9.1. Intra-cranial administration
Data were plotted as mean 7 standard error of the mean
(SEM). Statistical tests used were either a one- or two-way
ANOVA with post-test analysis performed using Bonferroni's
multiple comparison test. P-values less than 0.05 were con-
sidered signiﬁcant.
4.9.2. Intranasal-to-CNS
A ﬁxed effects model, including group, time, and group by time
interaction as ﬁxed effects, was ﬁt to the FcRn variant concen-
tration data (Wolfsegger and Jaki, 2005; Wolfsegger, 2007). For
each FcRn variant group, with application of the trapezoidal rule,
area under the curve (AUC) measurements: AUC (0-Last) (AUC of
mean concentration from 0min to 90min) were calculated based
on the mean concentrations across three time points and under
the assumption of zero concentration at time 0. Group mean
concentrations by time were estimated and 95% conﬁdence
intervals were constructed. FcRn variant effects were examined
using group AUCs as linear functions of themean concentrations
at three times. The Delta method was applied for the inference
of between-group AUC differences. All the 95% conﬁdence
intervals were two-sided t-type intervals and all P-values
were from two-sided t-tests. For all tests, P-values less than
0.05 were considered signiﬁcant (Wolfsegger and Jaki, 2005;
Wolfsegger, 2007).Acknowledgments
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